



Nurix Therapeutics Announces Upcoming Scientific Presentation for its CBL-B Program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)

October 22, 2019

SAN FRANCISCO, October 22, 2019 – Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that it will present data on its wholly-owned, CBL-B small molecule drug development program at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019). SITC is being held on November 6-10, 2019 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

Presentation Details:

Title: Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target
Poster #: P669
Date: Friday, November 8, 2019
Time: 7:00 a.m. – 8:00 p.m. EST

About Nurix Therapeutics

Nurix Therapeutics develops therapies that control disease-causing proteins. Nurix's pipeline is focused on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally recognized experts in E3 ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit <http://www.nurixtx.com>.

Media Contact

Sara Zelkovic
LifeSci Public Relations
Sara@lifescipublicrelations.com